Workshop on Pharmacogenomics: from science to clinical care Session - PowerPoint PPT Presentation

Aug 28, 2023 •31 likes •61 views

Workshop on Pharmacogenomics: from science to clinical care Session 4 : Pharmacogenomics guided treatments in clinical care: experience from patients and healthcare professionals London, October 8-9, 2012 David H.-U. Haerry, EATG

Workshop on Pharmacogenomics: from science to clinical care Session 4 : Pharmacogenomics guided treatments in clinical care: experience from patients and healthcare professionals London, October 8-9, 2012 David H.-U. Haerry, EATG
✔ Pharmacogenomics in HIV/HCV A lot of experience accumulated ✓ Hypersensitivity testing pre-abacavir use (HLA B*5701 genetic test) ✓ IL28B polymorphism (HCV) ✓ Studies show genetic factors influence plasma concentrations in NNRTI (983T>C genotypes) ✓ Tropism testing pre-maraviroc use
✔ Areas of urgent improvement ✓ Pharmacogenetic testing to be an option in phIII pivotal trials for cases of hepatoxicity, hypersensitivity, rash – address IC, data protection ✓ Interpretation pharmacogenetic testing ✓ Regulatory differences FDA/AUS/EMA when better assays become available – case of Maraviroc

Recommend

Session 3: Post-approval pharmacogenomics: impact on Risk Management Workshop on

Session 3: Post-approval pharmacogenomics: impact on Risk Management Workshop on Pharmacogenomics: from Science to clinical care 8 October 2012 Presented by: Isabelle Moulon Head of Medical Information An agency of the European Union

239 views • 8 slides

Genomics in Patients with Hispanic ancestry - Pharmacogenetics in Hispanics and Its clinical

EMA Workshop on Pharmacogenomics: from science to clinical care October 8-9, 2012 Genomics in Patients with Hispanic ancestry - Pharmacogenetics in Hispanics and Its clinical implications - Adrin LLerena MD PhD Clinical Research Centre

339 views • 29 slides

Elisabeth George, Technology Appraisals Centre for Health Technology Evaluation, NICE Workshop on

HTA of Companion Diagnostics Elisabeth George, Technology Appraisals Centre for Health Technology Evaluation, NICE Workshop on Pharmacogenomics: from science to clinical care 8-9 October 2012 European Medicines Agency, London, United Kingdom

411 views • 23 slides

Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies Mike

Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies Mike Pacanowski, PharmD, MPH Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug

659 views • 26 slides

Evaluation & Implementation Challenges with Genomic Signatures in Clinical Drug Development

April 3-4, 2006 Evaluation & Implementation Challenges with Genomic Signatures in Clinical Drug Development V. Devanarayan, Ph.D. Exploratory Statistics, Pharmaceutical R&D Abbott EMA Workshop on Pharmacogenomics: From Science to

572 views • 18 slides

Differences in a biomarkers predictive ability across racial groups Steve Lewitzky, Novartis

Differences in a biomarkers predictive ability across racial groups Steve Lewitzky, Novartis Pharmaceuticals EMA Workshop on Pharmacogenomics: from science to clinical care October 9, 2012 Overview Introduction: Differences in

465 views • 17 slides

PHARMACOGENOMICS AN INTRODUCTION TO PERSONALIZED MEDICINE Megan Penner-Willis, PharmD Clinical

PHARMACOGENOMICS AN INTRODUCTION TO PERSONALIZED MEDICINE Megan Penner-Willis, PharmD Clinical Assistant Professor UAA/ISU Doctor of Pharmacy Program DISCLOSURES I do not have (nor does any immediate family member have) a vested interest in

554 views • 37 slides

Regulation, innovation and personalised medicine The governance of pharmacogenomics in Europe

Regulation, innovation and personalised medicine The governance of pharmacogenomics in Europe and the USA Presentation at EMA workshop, London, October 2012 Dr Stuart Hogarth Department of Social Science, Health and Medicine, Kings College

243 views • 22 slides

Pharmacogenomics: Regulatory Considerations for the Next Generation of Medicines Hobart Rogers,

Pharmacogenomics: Regulatory Considerations for the Next Generation of Medicines Hobart Rogers, Pharm.D., Ph.D., Genomics and Targeted Therapies Group Office of Clinical Pharmacology FDA The views expressed are those of the speakers and do

769 views • 60 slides

Pharmacogenomics: Providing Personalized Medicine April 28, 2020 Russ B. Altman, PhD, MD

Pharmacogenomics: Providing Personalized Medicine Pharmacogenomics: Providing Personalized Medicine April 28, 2020 Russ B. Altman, PhD, MD Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy)

846 views • 23 slides

The College of St. Scholastica, Duluth, MN Background We need to move the pharmacogenomics

Strategies for Infusing Pharmacogenomics into NP Education Sara McCumber, DNP, APRN, CNP, CNS The College of St. Scholastica, Duluth, MN Background We need to move the pharmacogenomics conversation beyond grapefruit juice and simvastatin!!! The

340 views • 3 slides

Informatics challenges for pharmacogenomics Russ B. Altman, MD, PhD Departments of

Informatics challenges for pharmacogenomics Russ B. Altman, MD, PhD Departments of Bioengineering & Genetics PharmGKB, http://www.pharmgkb.org/ Stanford University Four stories about pharmacogenomics 1. Building a knowledge repository for

847 views • 72 slides

Pharmacogenomics as a proof of principal for genomic medicine: emphasis on real endpoints

Pharmacogenomics as a proof of principal for genomic medicine: emphasis on real endpoints December 5, 2011 Dr Howard L. McLeod Eshelman Distinguished Professor and Director Institute for Pharmacogenomics and Individualized Therapy (IPIT)

405 views • 24 slides

12 th International IACFS/ME Conference Emerging Science & Clinical Care Ft. Lauderdale,

12 th International IACFS/ME Conference Emerging Science & Clinical Care Ft. Lauderdale, October 27-30, 2016 One Persons Highlights of the Biological Research Presentations Anthony L. Komaroff, M.D. Since the 2014 San Francisco Meeting

604 views • 28 slides

Integrating Pharmacogenomics into Decision Making Munir Pirmohamed David Weatherall Chair of

Integrating Pharmacogenomics into Decision Making Munir Pirmohamed David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University of

337 views • 22 slides

Clinical view on current Standard of Care in NMO R. MARIGNIER MD, PhD Service de Neurologie A et

Regulatory Workshop on Clinical Trials Designs in Neuromyelitis Optica (NMO) and Spectrum Disorders Clinical view on current Standard of Care in NMO R. MARIGNIER MD, PhD Service de Neurologie A et Centre de Coordination EDMUS sur la Sclrose en

394 views • 23 slides

Pharmacogenomics and Therapeutic Target Validation of Cardiovascular Disease Models Toshio Tanaka

Pharmacogenomics and Therapeutic Target Validation of Cardiovascular Disease Models Toshio Tanaka MD, PhD Department of Molecular and Cellular Pharmacology Pharmacogenomics and Pharmacoinformatics Mie University Graduate School of Medicine

482 views • 24 slides

Clinical Integration and Collaborative Care: Clinical Integration and Collaborative Care:

Clinical Integration and Collaborative Care: Clinical Integration and Collaborative Care: Enforcement Meets Quality Enforcement Meets Quality Council of Deans Regional Fall Meeting September 7, 2007 Douglas A. Hastings Chair, Health Care and

1.12k views • 53 slides

The Role of Adaptive Designs in Clinical Development Program * Sue- -Jane Wang, Ph.D. Jane Wang,

The Role of Adaptive Designs in Clinical Development Program * Sue- -Jane Wang, Ph.D. Jane Wang, Ph.D. Sue Associate Director, Adaptive Design and Pharmacogenomics Associate Director, Adaptive Design and Pharmacogenomics Office of

540 views • 30 slides

Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm),

Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Universit de Montral Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy, Universit de Montral

427 views • 29 slides

Model of Care for 65 and over Dr. Richard Hooker Clinical Lead West London CCG Integrated Care

Model of Care for 65 and over Dr. Richard Hooker Clinical Lead West London CCG Integrated Care Team Paula Morrell Health & Social Care Assistant (HSCA) My Care My Way My Care My Way Service More Coordination Case Finding, Care

405 views • 13 slides

Genomics in science and clinical care Frdrique Nowak Institut National du Cancer October

Genomics in science and clinical care Frdrique Nowak Institut National du Cancer October 8, 2012 I nstitut national du cancer (I NCa) The French National Cancer Institute is a health and science agency dedicated to oncology.

204 views • 19 slides

Chronic disease care plans & Clinical templates At the practice I also created 50 robust

Chronic disease care plans & Clinical templates At the practice I also created 50 robust clinical templates that integrate best clinical management (NICE) to the daily consultation and clinical records. This helped reduced variations of care

249 views • 4 slides

EMA Workshop on NMO London, October 10, 2014 Eliezer Katz, MD FACS Senior Director, Clinical

Neuromyelitis Optica Is there a Standard of Care? EMA Workshop on NMO London, October 10, 2014 Eliezer Katz, MD FACS Senior Director, Clinical Development Immunosuppressive Therapy in NMO Standard of Care? Or Available, empiric,

339 views • 30 slides